Home > Drugs A – Z > Triamcinolone (By injection)

Triamcinolone (By injection)

Treats many diseases and conditions, especially problems related to inflammation. May reduce inflammation in joints. This medicine is a corticosteroid.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Triamcinolone injection is used to treat inflammation (swelling), allergic reactions, certain types of arthritis, gout, skin diseases, and many other medical problems. It is given to patients who are not able to take medicines by the mouth. This medicine is a corticosteroid (cortisone-like medicine or steroid). This medicine is to be administered only by or under the immediate supervision of your… Read more
Brand names include
Active Injection Kit KL-3, Active Injection Kit KM, Aristocort, Aristocort Forte, Aristospan, Arze-Ject-A, BT Injection Kit, Bupivilog Kit, Clinacort, DermacinRx Cinlone-I CPI, Interarticular Joint Kit, JTT Physicians Kit, Kenalog-10, Kenalog-40, LT Injection Kit, Lidolog Kit, MLK F1 Kit, MLK F2 Kit, MLK F3 Kit, Triam-Forte, Triamcot, Triesense, Zilretta
Other forms
For the teeth or gums, Into the nose, Intra-articular route, On the skin
Drug classes About this
Endocrine-Metabolic Agent, Immune Suppressant
Combinations including this drug

What works? Research summarized

Evidence reviews

Effectiveness and safety of laser photocoagulation plus intravitreal triamcinolone for diabetic macular edema: a meta-analysis

Bibliographic details: Xu CQ, Ma LJ.  Effectiveness and safety of laser photocoagulation plus intravitreal triamcinolone for diabetic macular edema: a meta-analysis. Chinese Journal of Evidence-Based Medicine 2012; 12(7): 817-821 Available from: http://www.cjebm.org.cn/oa/DArticle.aspx?type=view&id=2012070014

Clinical course and management of iatrogenic Cushing's syndrome after co-administration of injected-triamcinolone and ritonavir: a systematic review

Bibliographic details: John G, Ollo D, Meyer P, Herold M, Samer CF, Calmy A.  Clinical course and management of iatrogenic Cushing's syndrome after co-administration of injected-triamcinolone and ritonavir: a systematic review. Journal of Antivirals and Antiretrovirals 2013; 5(7): 180-184 Available from: http://omicsonline.org/clinical-course-and-management-of-iatrogenic-cushing-syndrome-jaa.1000086.php?aid=22049

Systemic corticosteroids for acute gout

‐ there is no precise information about side effects and complications. Only a minority of the patients treated with the steroid oral prednisolone reported minor side effects.

See all (131)

Summaries for consumers

Systemic corticosteroids for acute gout

‐ there is no precise information about side effects and complications. Only a minority of the patients treated with the steroid oral prednisolone reported minor side effects.

Intravitreal steroids for macular edema in people with diabetes

Macular edema, swelling of the center of the retina (the part of the eye responsible for our sharpest vision), is an important cause of poor vision in patients with diabetes. New forms of therapy are desirable because the current treatment including laser photocoagulation does not control all cases of diabetic macular edema (DME) and because laser therapy may destroy normal retinal tissue. Intraocular steroids in the form of intravitreal triamcinolone acetate injection (IVTA) and surgical implantation of fluocinolone acetonide (FAI) or dexamethasone drug delivery system (DDS) are promising new therapies. This systematic review included seven randomized clinical trials involving 632 eyes from five countries evaluating the effectiveness and safety of intravitreal steroids for treating DME. Two trials were at low risk of bias, one was at median risk of bias, two were at high risk of bias, and the remaining two had an unclear risk of bias. In this systematic review, the preponderance of data suggest a beneficial effect from IVTA. The average improvement in visual acuity was 7.5 letters more (‐0.15 LogMAR; 95% CI ‐0.21 to ‐0.09) in the IVTA treated eyes than in those treated with other therapies at three months (based on three trials), 11.5 letters more (‐0.23 LogMAR; 95% CI ‐0.33 to ‐0.13) at six months (two trials), 14.5 letters more (‐0.29 LogMAR; 95% CI ‐0.47 to ‐0.11) at nine months (one trial), and 5.7 letters more (‐0.11 LogMAR; 95% CI ‐0.20 to ‐0.03) at 24 months (one trial). Improved clinical outcomes were also reported in FAI and dexamethasone DDS trials. Elevation of intraocular pressure and cataract progression occur in both IVTA and implants treated eyes but appear manageable.

Topical corticosteroids for treating phimosis in boys

Phimosis is a condition where the foreskin cannot be fully drawn back (retracted) over the penis. Phimosis is normal at birth and often self‐corrects without needing treatment during the first three to four years of life; only 10% of three year old boys have phimosis. This is known as congenital phimosis. Phimosis can also be caused by scarring of the skin protecting the head of the penis that is caused when the foreskin cannot be retracted. Phimosis caused by scarring is estimated to occur among 0.6% to 1.5% of boys less than 18 years of age, but this type of phimosis seldom occurs among boys under five years of age. Making a distinction between types of phimosis can sometimes be difficult.

See all (23)

PubMed Health Blog...

read all...